Get the Stockscreener App
718.15
0.41%
2.96
After Hours:
718.15
Regeneron Pharmaceuticals Inc stock is traded at $718.15, with a volume of 535.53K.
It is up +0.41% in the last 24 hours and down -4.19% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$715.19
Open:
$716.07
24h Volume:
535.53K
Relative Volume:
0.69
Market Cap:
$78.92B
Revenue:
$13.85B
Net Income/Loss:
$4.65B
P/E Ratio:
17.77
EPS:
40.41
Net Cash Flow:
$3.32B
1W Performance:
+0.81%
1M Performance:
-4.19%
6M Performance:
-29.87%
1Y Performance:
-21.73%
1-Day Range:
$714.76
$722.00
1-Week Range:
$700.42
$726.81
52-Week Range:
$693.00
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by RK Asset Management LLC - MarketBeat
Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular - Scrip
Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Simply Wall St
Regeneron expands in eye care with Oxular deal (REGN:NASDAQ) - Seeking Alpha
Regeneron eyes novel drug delivery with Oxular buy - The Pharma Letter
1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street - MSN
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
(REGN) Investment Report - Stock Traders Daily
Eosinophilic Esophagitis Market Insight, Epidemiology and Market Forecast to 2034 - GlobeNewswire Inc.
Interleukins Market Is Booming Worldwide 2024-2031 | Novartis - openPR
Jim Cramer’s Take on Regeneron Pharmaceuticals (REGN): Bold Predictions for the Future - Insider Monkey
Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their decent 89% return over the last five years - Yahoo Finance
Age-related Macular Degeneration Treatment Market 2034: FDA Approvals, Drugs, Medication, and Companies by - EIN News
Regeneron reports positive results for two anti-coagulant drugs - MSN
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Homozygous Familial Hypercholesterolemia Market is Set - openPR
US FDA revokes authorization for four COVID antibody drugs - Reuters
Red Biotechnology Market Growth, Trends & Key Players Analysis - openPR
(REGN) Investment Analysis - Stock Traders Daily
Regeneron Down 15.5% Year to Date: How to Play the Stock? - MSN
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Regeneron advances anticoagulant antibody program - The Pharma Letter
Principal Financial Group Inc. Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
REGNRegeneron Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible - GlobeNewswire
Regeneron Will Move Two Factor XI Agents Into Phase III - News & Insights
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Regeneron says study data support big bet on new blood thinners - BioPharma Dive
Cutaneous Squamous Cell Carcinoma Market Set to Grow - openPR
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results - The Manila Times
Regeneron To Advance Two Factor Xi Antibodies Into A Broad Phase 3 Program - XM
Regeneron posts Phase 3 win for Eylea HD in retinal vein occlusion - MSN
Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 52-Week LowHere's What Happened - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study - Nasdaq
Broader Eylea HD label on the cards after Phase III win - The Pharma Letter
Atopic Dermatitis: A Crowded Field With Room To Grow - News & Insights
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Lowered by Canaccord Genuity Group - MarketBeat
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Regeneron to Present at J.P. Morgan Healthcare Conference 2025: Strategic Updates Expected - StockTitan
Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease StudyRegeneron Pharmaceuticals (NASDAQ:REGN) - Benzinga
Regeneron, Bayer Build Retinal Vein Occlusion Case for Eylea as Biosimilar Pressure Mounts - BioSpace
Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Hold Rating from Analysts at Canaccord Genuity Group - MarketBeat
EYLEA HD achieves comparable vision gains with fewer doses - Investing.com
Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Insider Monkey
Canaccord Genuity Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Hold Recommendation - MSN
Regeneron, Allele Settle Covid Cocktail Patent Infringement Suit - Bloomberg Law
Allele, Regeneron Settle COVID Treatment Patent Suit - Law360
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year - The Manila Times
Regeneron settles patent lawsuit over protein for testing COVID-19 treatments - Reuters
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):